Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas study.

Saved in:
Bibliographic Details
Title: Resistance to novel β-lactam/β-lactamase inhibitors among carbapenem-resistant Pseudomonas aeruginosa and clinical implications in the prospective observational Pseudomonas study.
Authors: Gottesdiener LS; Weill Cornell Medicine, New York, New York, USA.; NewYork-Presbyterian Hospital, New York, New York, USA., Li Y; The Biostatistics Center, George Washington University, Rockville, Maryland, USA., Greenwood-Quaintance KE; Mayo Clinic, Rochester, Minnesota, USA., Komarow L; The Biostatistics Center, George Washington University, Rockville, Maryland, USA., Arias CA; Houston Methodist Hospital, Houston, Texas, USA., Cober E; Cleveland Clinic, Cleveland, Ohio, USA., Herc ES; Henry Ford Hospital, Detroit, Michigan, USA., Kaye KS; Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA., Huskins WC; Mayo Clinic, Rochester, Minnesota, USA., Figueroa J; Hospital Universitario Erasmo Meoz ESE, Cúcuta, Colombia., Vilchez S; University of North Carolina, Chapel Hill, North Carolina, USA., Fries BC; Stony Brook University, Stony Brook, New York, USA., Leroi M; The Austin Hospital, Heidelberg West, Victoria, Australia., McCarty TP; University of Alabama at Birmingham, Birmingham, Alabama, USA., Rioseco ML; Facultad de Medicina, Universidad San Sebastián, Sede Patagonia, Concepción, Chile., Munita JM; Facultad de Medicina Clínica Alemana, Universidad del Desarrollo, Santiago, Chile., Stryjewski ME; Centro de Educación Médica e Investigaciones Clínicas, Buenos Aires, Argentina., Reyes J; Molecular Genetics and Antimicrobial Resistance Unit, Universidad El Bosque, Bogotá, Colombia., Chen L; School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York, USA., Kreiswirth BN; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA., Hill C; Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA., Baum K; Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA., Villegas MV; Grupo de Investigación en Resistencia Antimicrobiana y Epidemiología Hospitalaria, Universidad El Bosque, Bogotá, Colombia.; Clínica Imbanaco Grupo Quirónsalud, Cali, Colombia., Paterson DL; Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.; National University of Singapore, Singapore, Singapore., Bonomo RA; Clinical Scientist Investigator, Medical and Research Service, Louis Stokes Cleveland Department of Veterans Affairs Medical Center, Cleveland, Ohio, USA., Chambers HF; University of California San Francisco, San Francisco, California, USA., Fowler VG Jr; Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA.; Duke University Medical Center, Durham, North Carolina, USA., Patel R; Mayo Clinic, Rochester, Minnesota, USA., Doi Y; University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., van Duin D; University of North Carolina, Chapel Hill, North Carolina, USA., Satlin MJ; Weill Cornell Medicine, New York, New York, USA.; NewYork-Presbyterian Hospital, New York, New York, USA.
Corporate Authors: Antibacterial Resistance Leadership Group
Source: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2026 Jun 03; Vol. 70 (6), pp. e0038825. Date of Electronic Publication: 2026 May 15.
Publication Type: Journal Article; Multicenter Study; Observational Study
Journal Info: Publisher: American Society for Microbiology Country of Publication: United States NLM ID: 0315061 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-6596 (Electronic) Linking ISSN: 00664804 NLM ISO Abbreviation: Antimicrob Agents Chemother Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1098-6596
DOI:10.1128/aac.00388-25